Current and Emerging Treatment Regimens for HER2-Positive Breast Cancer

about

HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance.The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer.

P2860

Q33737278-C9A4ACD2-7858-494A-BAE9-B0D907397D8A Q49887915-3AE086B3-5A27-40F5-8286-D833BE97F588

P2860

Current and Emerging Treatment Regimens for HER2-Positive Breast Cancer

Item

http://www.wikidata.org/entity/Q37733237

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Current and Emerging Treatment Regimens for HER2-Positive Breast Cancer

@en

Current and Emerging Treatment Regimens for HER2-Positive Breast Cancer.

@nl

type

Item

label

Current and Emerging Treatment Regimens for HER2-Positive Breast Cancer

@en

Current and Emerging Treatment Regimens for HER2-Positive Breast Cancer.

@nl

prefLabel

Current and Emerging Treatment Regimens for HER2-Positive Breast Cancer

@en

Current and Emerging Treatment Regimens for HER2-Positive Breast Cancer.

@nl

P1476

Current and Emerging Treatment Regimens for HER2-Positive Breast Cancer

@en

P2093

Maribeth Maher

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Trastuzumab--mechanism of action and use in clinical practice

P304

206-212

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24790399

http://www.w3.org/2001/XMLSchema#string

P932

4005117

http://www.w3.org/2001/XMLSchema#string

Current and Emerging Treatment Regimens for HER2-Positive Breast Cancer

about

P2860

P2860

Current and Emerging Treatment Regimens for HER2-Positive Breast Cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932